Targeting multiple pathways in gliomas with stem cell and viral delivered S-TRAIL and Temozolomide.
AuthorsHingtgen S, Ren X, Terwilliger E, Classon M, Weissleder R, Shah K,
JournalMol Cancer Ther
PubMed ID19001440
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) selectively kills tumor cells. However, its short half-life, poor delivery, and TRAIL-resistant tumor cells have diminished its clinical efficacy. In this study, we explored whether novel delivery methods will represent new and effective ways to treat gliomas and if adjuvant therapy with the chemotherapeutic ... More